Novo Nordisk Faces Challenges After Rapid Expansion

Post by : Monika

Photo: Reuters

Novo Nordisk, a major pharmaceutical company from Denmark, experienced significant growth over the past five years, mainly due to the success of its weight-loss drug, Wegovy. During this period, the company nearly doubled its workforce, expanding from around 43,260 employees in 2019 to 77,350 by the end of 2024.

While this rapid growth initially helped the company meet rising demand, it also increased costs and created operational challenges. As a result, Novo Nordisk is now considering cost-cutting measures, including potential layoffs.

Rapid Expansion Fueled by Wegovy’s Success

Wegovy became extremely popular and drove a surge in sales for Novo Nordisk. To meet this demand, the company expanded its manufacturing capacity and sales teams aggressively. Over five years, the company hired an average of 131 new employees each week. By comparison, rival Eli Lilly grew its workforce from 36,000 to 47,000 during the same period.

Initially, this growth was seen as a sign of strong performance. However, the rapidly growing workforce significantly increased employee-related expenses, which nearly doubled to $9.9 billion by the end of last year. Rising costs put pressure on profit margins, which fell to their lowest level in two and a half years.

Challenges and Increased Competition

Despite Wegovy’s initial success, Novo Nordisk now faces several challenges. Sales of the drug have started to slow, and competition is increasing from Eli Lilly’s Zepbound and cheaper generic alternatives in the U.S. These factors have contributed to a large decline in the company’s market value, with an estimated $490 billion lost since its peak last year.

In response, Novo Nordisk appointed Maziar Mike Doustdar as CEO in August 2025. Doustdar immediately introduced a global hiring freeze for non-critical roles and began reviewing all costs, including salaries. He emphasized exploring every possible way to reduce expenses and improve financial stability.

Potential Layoffs and Organizational Restructuring

As part of its cost-cutting efforts, layoffs are under consideration, particularly in areas that expanded quickly. Analysts expect the sales division to be most affected, especially after the company deprioritized its older diabetes drug, Rybelsus. Sales of Rybelsus have declined, overshadowed by the high demand for Ozempic, which contains the same active ingredient as Wegovy.

Novo Nordisk also created a new U.S. sales team to market certain products separately from the Ozempic team. This expansion sometimes led to overlapping outreach to the same healthcare providers, raising questions about organizational efficiency.

In addition to potential layoffs in sales, administrative and communications departments may also face reductions. Manufacturing staff, who were hired during factory expansions, are likely to be spared initially to maintain production. However, all areas of the company are being reviewed to find cost savings.

Strategic Adjustments and Future Outlook

To improve profitability and financial health, Novo Nordisk is taking strategic steps. These include the global hiring freeze, cost reviews, and potential restructuring.

Despite challenges, the company remains committed to long-term goals. It continues to invest in research and development to introduce new treatments. Additionally, Novo Nordisk is exploring ways to expand its product line and strengthen its global position in the pharmaceutical market.

Novo Nordisk’s rapid growth, driven by the success of Wegovy, has created operational and financial challenges. Slowing sales and rising competition have led the company to consider cost-cutting measures, including potential layoffs.

Under CEO Maziar Mike Doustdar, Novo Nordisk is implementing strategic adjustments to improve profitability and ensure long-term success. While navigating these challenges, the company continues to focus on its mission to provide innovative treatments and improve patient outcomes worldwide.